Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.

Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

Abstract: The present invention provides, inter alia, a composition containing a compound of formula (I): or a pharmaceutically acceptable salt thereof, optionally, in combination with at least one immune checkpoint inhibitor compound. Kits containing the composition, and methods of using the composition for ameliorating or treating the effects of a disease such as a cancer, in a subject, are also provided herein.

Abstract: The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.

Abstract: The present invention provides methods for treatment of a RAS-positive disease, in particular KRAS-positive non-small cell lung cancer as well as a method for potentiating the apoptotic activity of a PDE? inhibitor by combining the PDE? inhibitor with a direct autophagy inhibitor. The PDE? inhibitor is preferably, but not exclusively, deltarasin, and the direct autophagy inhibitor is in particular 3-methyladenine. Further provided by the present invention are a kit and a pharmaceutical composition comprising the PDE? inhibitor and a direct autophagy inhibitor. The methods of the present invention in particular provide a new treatment option for RAS-positive diseases such as KRAS-positive non-small cell lung cancer allowing for an increased apoptotic activity of the PDE? inhibitor by simultaneously blocking its “tumor protective” autophagy.

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteolytic bone metastases, with a dual inhibitor of MET and VEGF.

Abstract: Provided herein are methods for treating cancer relating to inhibition of PI3K, as pharmaceutical compositions comprising a PI3K inhibitor and a PAK1 inhibitor.

Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.

Abstract: Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.

Abstract: The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.

Abstract: Described herein are oral abuse deterrent pharmaceutical compositions, methods for making the same, and methods for treating pain by administering the pharmaceutical composition to a subject in need thereof. In particular, an oral abuse deterrent pharmaceutical composition comprising a soft capsule and a controlled release matrix comprising oxycodone are described.

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Abstract: Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.

Abstract: Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.

Abstract: Compounds of the formula I in which X, Y, Q1, M, Q2 and B have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

Abstract: Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Abstract: The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.

Abstract: A medicament for therapeutic and/or preventive treatment of Alzheimer's disease, which comprises a combination of a retinoic acid receptor (RAR) agonist such as Am80 and a retinoid X receptor (RXR) agonist such as HX630.

Abstract: Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7?, Z, Y, n, y, and x, are as defined herein.

Abstract: The present invention relates to asthma. Particularly, the present invention relates to clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development for the treatment of asthma. The present invention relates to a new paradigm in diagnosing, screening, and treating asthma by affecting airway epithelial synchronization.

Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Abstract: Provided herein are sulfate free and/or sodium chloride free scalp treatment compositions comprising corticosteroid, combinations containing these compositions, kits and methods, particularly for treating and/or preventing itchy scalp.

Abstract: A dental composition comprising a therapeutically effective amount of doxycycline hyclate and a therapeutically effective amount of triamcinolone acetonide and use in dental treatment.

Abstract: Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway.

Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as knee pain.

Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.

Abstract: The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent.

Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3 h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC-like cells that show phenotype of advanced cancer relapsing.

Abstract: Low levels of resistant potato starch, for example, 0.5-1.0% of total diet, have a beneficial effect on post-weaning diarrhea, infectious diarrhea and gastrointestinal stresses associated with weaning. Also described are capsules and tablets of resistant potato starch, and methods for making said capsules and tablets.

Abstract: The present invention relates to advanced topical formulations of pharmaceutically acceptable salts of Heparin providing enhanced transdermal penetration. The present invention provides clear, non-sticky liquid formulations in which the drug is ready-for-absorption and which are suitable for administration in the form of a solution or a spray. The topical formulations of the present invention do not form flaky or gel-like film on skin surface upon topical application.

Abstract: Sperm mobility and impregnation of an oocyte is enhanced by placing sperm in an aqueous solution of phospholipids prior to in vitro fertilization or artificial insemination. The aqueous phospholipid solution can also be used during storage or cryopreservation of the sperm. Also, the motility of sperm produced or ejaculated and the environment into which it is placed is enhanced my ingestion of the phospholipid composition by the male or female, or a vaginal placement of compositions containing the phospholipids.

Abstract: A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment.

Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.

Abstract: The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells.

Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.

Abstract: Methods of manufacturing a bone-derived extracellular matrix (bECM) product are provided. Also provided are bECM products and methods of using those products.

Abstract: The present invention provides a composition including a poly-l-lactic acid (PLLA) and polylactic-co-glycolic-acid (PLGA) scaffold on which neuronal tissue is grown ex-vivo. Furthermore, the invention provides a method for making ex-vivo cellular vasculature networks, and a method for treating a neuronal injury in a subject by implanting the current composition.

Abstract: A traditional Chinese medicine complex composite for significantly improving high density lipoprotein (HDL) concentration in serum, includes: a tablet which includes 30%-50% hawthorn from north China, 10%-30% radix aucklandiae, 10%-30% radix glehniae and 10%-30% ligusticum wallichii; and a powder which includes 40%-60% beef, 15%-35% bovine sinew, 15%-35% pigskin and 0.5%-2.5% Chinese-date. The tablet is prepared by decocting and boiling the raw material medicine with water, and the powder is prepared by catalytic hydrolysis with an enzyme, the pigskin in the powder can be replaced with bovine skin or donkey skin, and the bovine sinew can be replaced with bovine tendon.

Abstract: The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.

Abstract: Molecules secreted or derived from probiotic bacteria are provided for use in compositions and methods for the treatment and/or prevention of infection by pathogenic viruses. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

Abstract: In a first aspect, the present invention relates to new compositions comprising new bacteriophages allowing the prophylactic or therapeutic treatment of Salmonella infections in mammals and birds. Moreover, the present invention relates to the method for fighting Salmonella comprising the step of treating matter suspected to be afflicted with Salmonella with the bacteriophages according to the present invention. Moreover, the present invention relates to a method of treating or preventing Salmonella infection, in particular, in livestock.

Abstract: This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided.